TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05890105
Drug: PF-07853578
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.
Study: NCT05623774
Drug: Imatinib Mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400mg tablet
Study: NCT05623774
Drug: IkT-001Pro
Normalized name: IKT-001Pro
DrugBank: IKT-001Pro (DB17307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg or 400mg tablet
Study: NCT06656169
Drug: Subcutaneous polyvidone collagen
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use collagen-polyvidone at a dose of 0.2 ml, applied to the affected area of the hand.
Study: NCT06656429
Drug: Transforaminal Epidural Steroid Injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal Epidural Steroid Injections
Study: NCT05466838
Drug: PERT at discharge
Normalized name: rose bengal AT
DrugBank: Rose bengal (DB11182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day. Dose escalation 100,000 units lipase with meals and 50,000 units with snacks.
Study: NCT05522517
Drug: Cosentyx
Normalized name: Cosentyx
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cosentyx injection will be administered subcutaneously.
Study: NCT05522517
Drug: Candin
Normalized name: Candin
DrugBank: Candida albicans (DB10429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candin will be administered interadermally along with NaCl solution.
Study: NCT06656351
Drug: Tafenoquine 100mg
Normalized name: TAFENOQUINE 100MG TAB
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tafenoquine
Study: NCT05126238
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In preoperative period patients will take 300 mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will take 300mg of lithium carbonate 2 hours before surgery.
Study: NCT06657209
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 weeks started at 2.5mg/week and increased to 5mg/week dose
Study: NCT06657209
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 weeks at a 45mg/day dose
Study: NCT05134857
Drug: Zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The ZON will be supplied in 100 mg capsules and deposited directly into the TAD device by research staff every 2 weeks. All participants will be told to take 100 mg/day for the first three weeks (Week 1-2 single-blind, placebo-only, induction; end of Week 2, active treatment begins) and increasing by 100 mg/day every other week (Week 4: 200 mg/day; Week 6: 300 mg/day; Week 8: 400 mg/day) up to the target dose of 500 mg/day by Week 10. The participants will be maintained on this dose through Week 14 of active treatment and then tapered off ZON (2 weeks). This dosing schedule is consistent with best practices for ZON. All TAD devices will only dispense the prescribed medication between 4pm and 11pm each night. Participants will be instructed to take the medication at or near bedtime.
Study: NCT05505409
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug:pirfenidone CTD-ILD patients treated with pirfenidone up to the maximum tolerable dose Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
Study: NCT05505409
Drug: glucocorticoid and immunosuppressant
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: glucocorticoid and immunosuppressant CTD-ILD patients treated with glucocorticoid and immunosuppressant according to the condition of the disease
Study: NCT06479603
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The subjects will receive oral nintedanib. It will be prescribed to be taken after meals with 12 hrs gap between doses. The drug will be started at a dose of 100 mg twice daily. After 2 weeks, the dose will be titrated up to 150 mg twice daily, which will be continued till the end of 52 weeks. The standard-of-care immunosuppressive treatment will be continued along with the study drug (nintedanib). In case of intolerance to the 300 mg/day dose of nintedanib, the dose will be reduced to 100 mg twice daily. In case of severe adverse effects, the drug will be stopped and reintroduced after a period of up to 1-4 weeks. A dose of 100 mg twice daily will be started and continued. One attempt to titrate the dose up to 150 mg twice daily will be permitted.
Study: NCT05631028
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.
Study: NCT05631028
Drug: Remimazolam tosilate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.
Study: NCT06617481
Drug: 18F-rhPSMA-7.3 (Posluma)
DrugBank: Flotufolastat F-18 (DB17851)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET Scan using Posluma for detection of early recurrence of prostate cancer.
Study: NCT05073692
Drug: DPP4
Normalized name: IMMUNOGLOBULIN G2B-KAPPA, ANTI-(HOMO SAPIENS DPP4(DIPEPTIDYLPEPTIDASE 4, DIPEPTIDYLPEPTIDASE IV, ADENOSINE DEAMINASE COMPLEXING PROTEIN 2, ADCP2, TP103, T CELL ACTIVATION ANTIGEN CD26, CD26)), MUS MUSCULUS MONOCLONAL ANTIBODY
DrugBank: Begelomab (DB13241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)
Study: NCT05073692
Drug: GLP-1RA
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)
Study: NCT05073692
Drug: SGLT2i or GLP-1RA
Normalized name: edaravone
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Exposure to either SGLT2i or GLP-1RA
Study: NCT05073692
Drug: Linagliptin (DPP4)
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Exposure to agent Linagliptin (DPP4)
Study: NCT05073692
Drug: Exenatide (GLP-1RA)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure to agent Exenatide (GLP1-RA)
Study: NCT05073692
Drug: Liraglutide (GLP-1RA)
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Exposure to agent Liraglutide (GLP-1RA)
Study: NCT05073692
Drug: Empagliflozin (SGLT2i)
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Exposure to agent Empagliflozin (SGLT2i)
Study: NCT05073692
Drug: Glimepiride (SU)
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure to agent Glimepiride (SU)
Study: NCT05073692
Drug: Glipizide (SU)
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure to Glimepiride (SU)
Study: NCT05073692
Drug: Glimepiride (SU) or Glipizide (SU)
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure to agent Glimepiride (SU) or Glipizide (SU)
Study: NCT05073692
Drug: Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
Study: NCT04561180
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The comparator, Administered as an Intravenous infusion
Study: NCT05888831
Drug: BMS-986449
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05888831
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT05006170
Drug: DTG DT 20 mg
Normalized name: L-DT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Give 2 tabs of MYLTEGA DT (10mg) PO once daily
Study: NCT05006170
Drug: DTG DT 25 mg
Normalized name: L-DT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Give 2.5 tabs of MYLTEGA DT (10mg) PO once daily
Study: NCT04840667
Drug: REPLAGAL
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.
Study: NCT05109312
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg
Study: NCT05109312
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125 mg
Study: NCT06060301
Drug: sulfasalazine 500 MG
Normalized name: sulfasalazine 500 MG
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.
Study: NCT06494878
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75-100 mg taken once daily by mouth.
Study: NCT06746753
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: randomized to receive Angiotensin II continuous infusion for up to 48 hours
Study: NCT06607029
Drug: the opioid-free anesthesia group
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be administered with an opioid-free strategy during surgery. The investigator will use esketamine, dexmetopidine, and local anesthesia to control perioperative pain.
Study: NCT03423355
Drug: Dapagliflozin (Forxiga®)
Normalized name: dapagliflozin Oral Tablet [Farxiga]
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg p.o. daily
Study: NCT03423355
Drug: Hydrochlorothiazide 25 mg
Normalized name: hydrochlorothiazide 25 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg p.o. daily
Study: NCT03423355
Drug: Placebo matching Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo matching Dapagliflozin p.o. daily
Study: NCT05127486
Drug: Galcanezumab
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC.
Study: NCT05127486
Drug: Rimegepant
Normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05402384
Drug: AVTX-801
DrugBank: VTX-801 (DB17646)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical grade D-galactose~dosage:2.0 g/kg/day
Study: NCT06642480
Drug: Post Operative Analgesia
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administering 100 mg of intravenous tramadol 30 minutes before the operation is completed
Study: NCT06642480
Drug: Post Operative Analgesia
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAS of 63 patients was determined by injecting tramadol at a dose of 100 mg 30 minutes before the operation was completed. It was observed in the recovery room at 30, 60, and 120 minutes.
Study: NCT06159478
Drug: Binimetinib 15 MG
Normalized name: binimetinib 15 MG
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Binimetinib 45mg is orally administered twice daily.
Study: NCT05113940
Drug: PF-07258669
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days
Study: NCT05113940
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669
Study: NCT05789992
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol (Random:3-5ug/ml)
Study: NCT05211167
Drug: Human Erythropoiesis Injection (CHO cell)
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
Study: NCT05211167
Drug: Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
Normalized name: Granulocyte colony stimulating factor 3 (CHO cell derived)
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
Study: NCT04912167
Drug: Sacubitril-Valsartan
Normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)
Study: NCT04912167
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)
Study: NCT04912167
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.
Study: NCT04714112
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous administration of dexamethasone at different time for the duration of ISB with 0.5% ropivacaine
Study: NCT04147949
Drug: AV-101
Normalized name: AV-101
DrugBank: AV-101 (DB12878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules taken twice daily for 14 days
Study: NCT05412706
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive Niraparib 200-300 mg orally as an individualized weight and platelet-based, flat-fixed, continuous daily dose.~Niraparib will be administered orally once daily in 28-day cycles.
Study: NCT04808687
Drug: Nab paclitaxel and S-1
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area \< 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 \< 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.
Study: NCT04871815
Drug: sodium pyruvate nasal spray
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will use a sodium pyruvate nasal spray 3x daily for 7 days.
Study: NCT05510986
Drug: Oxycodone Hydrochloride group
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dilute Oxycodone Hydrochloride injection (1ml:10mg) with 0.9% normal saline to~1mg/ml, 0.1mg/kg Oxycodone Hydrochloride is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.
Study: NCT05229965
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
Study: NCT05229965
Drug: Paracetamol caféine
Normalized name: Caféine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
Study: NCT04007276
Drug: brimonidine tartrate ophthalmic solution 0.025%
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.
Study: NCT04751500
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giving antibiotics to reduce any inflammation/infection caused by the retained pregnancy tissue allowing it to pass by itself
Study: NCT00040157
Drug: ACH126-443 (Beta-L-Fd4C)
Normalized name: Beta-l-thymidine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04512261
Drug: Tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Initial dosage of trial treatment for tucatinib will be given as 300 mg (dispensed as 2 x 150 mg tablets) orally twice a day for Days 1 - 21 of each 3-week cycle during the treatment period.
Study: NCT04512261
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial dosage of trial treatment for pembrolizumab will be given as 200 mg by intravenous infusion every 3 weeks on Day 1 of each 3-week cycle during the treatment period. Pembrolizumab will be administered for a maximum of 35 doses.
Study: NCT04512261
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial dosage of trial treatment for trastuzumab will be given as 8 mg/kg by intravenous (IV) infusion once on Day 1 of Cycle 1, and 6 mg/kg by IV every 3 weeks on Day 1 of each 3-week cycle starting on Cycle 2 during the treatment period.
Study: NCT06484166
Drug: Trolamine (Biafine)
Normalized name: Trolamine
DrugBank: Trolamine (DB13747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are instructed to apply a thin layer of the Trolamine (Biafine) third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.
Study: NCT04615871
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: semaglutide 0.25 mg s.c. on Day 0 after randomization, then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21
Study: NCT05899725
Drug: Corticosteroids and Ruxolitinib
Normalized name: abiraterone and corticosteroids
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence, add-on oral Ruxolitinib 5mg twice a day for 2 weeks, following with Ruxolitinib
Study: NCT06559436
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the TNK treatment group will receive TNK intravenous thrombolysis after MeVO is determined, and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg,
Study: NCT04723030
Drug: carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Carrilizumab ：200mg,q2w; Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days, and stopped for 2 weeks after radiotherapy.~Taxol :125mg/m2,q2w; Gemcitabine :1000mg/m2, q2w; cisplatin :25mg/m2, q2w; Radiotherapy:30Gy, divided into five times and completed within one week.
Study: NCT05091138
Drug: Adding Magnesium as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty
Normalized name: Aldex AN
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
Study: NCT05091138
Drug: Adding Buprenorphine as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty
Normalized name: Aldex AN
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
Study: NCT05593432
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Study: NCT05158348
Drug: Dexmedetomidine Hydrochloride
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group A will receive post-operative nebulised dexametomidine and lidocaine.
Study: NCT05158348
Drug: Nebulized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group B will receive post-operative will receive nebulised lidocaine